ALKEM LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of ALKEM LABORATORIES have increased by 2.34% YoY .
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 6.29 % YoY. |
||
ALKEM LABORATORIES Last 5 Annual Financial Results
[BOM: 539523|NSE : ALKEM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹12,965 Cr | ₹12,668 Cr | ₹11,599 Cr | ₹10,634 Cr | ₹8,865 Cr |
| Expenses | ₹10,452 Cr | ₹10,422 Cr | ₹9,990 Cr | ₹8,581 Cr | ₹6,923 Cr |
| Operating Profit (Excl OI) | ₹2,512 Cr | ₹2,245 Cr | ₹1,609 Cr | ₹2,053 Cr | ₹1,942 Cr |
| Other Income | ₹494 Cr | ₹311 Cr | ₹216 Cr | ₹163 Cr | ₹233 Cr |
| Interest | ₹122 Cr | ₹112 Cr | ₹107 Cr | ₹52 Cr | ₹59 Cr |
| Depreciation | ₹357 Cr | ₹299 Cr | ₹310 Cr | ₹304 Cr | ₹275 Cr |
| Profit Before Tax | ₹2,527 Cr | ₹2,023 Cr | ₹1,305 Cr | ₹1,844 Cr | ₹1,842 Cr |
| Profit After Tax | ₹2,216 Cr | ₹1,811 Cr | ₹1,007 Cr | ₹1,680 Cr | ₹1,618 Cr |
| Consolidated Net Profit | ₹2,165 Cr | ₹1,796 Cr | ₹984 Cr | ₹1,646 Cr | ₹1,585 Cr |
| Earnings Per Share (Rs) | ₹192.54 | ₹181.14 | ₹150.21 | ₹82.32 | ₹137.65 |
| PAT Margin (%) | 10.43 | 11.48 | 9.35 | 5.61 | 11.00 |
| ROE(%) | 18.29 | 19.93 | 18.74 | 11.39 | 20.99 |
| ROCE(%) | 21.28 | 21.56 | 19.52 | 13.09 | 18.69 |
| Total Debt/Equity(x) | 0.12 | 0.09 | 0.12 | 0.14 | 0.30 |
Key Financials |
||
| Market Cap | : | ₹ 63,987.8 Cr |
| Revenue (TTM) | : | ₹ 15,081.3 Cr |
| Net Profit(TTM) | : | ₹ 2,206.3 Cr |
| EPS (TTM) | : | ₹ 184.5 |
| P/E (TTM) | : | 29.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ALKEM LABORATORIES | -0.1% | -8% | -2.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -4% | 15.7% |
| DIVIS LABORATORIES | 9.1% | 18.2% | 47.1% |
| TORRENT PHARMACEUTICALS | 3.6% | 3.4% | 36.4% |
| CIPLA | -1.2% | -3.3% | -10.8% |
| DR REDDYS LABORATORIES | -1.4% | 2.9% | -8% |
| MANKIND PHARMA | 0.5% | -7.4% | -7.3% |
| LUPIN | -0.7% | -10.1% | 9.6% |
| ZYDUS LIFESCIENCES | 7.8% | 6.4% | 20.3% |
ALKEM LABORATORIES Revenues
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 2.34 % |
| 5 Yr CAGR | 9.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹12,965 Cr | 2.34 | |
| Mar2025 | ₹12,668 Cr | 9.21 | |
| Mar2024 | ₹11,599 Cr | 9.08 | |
| Mar2023 | ₹10,634 Cr | 19.96 | |
| Mar2022 | ₹8,865 Cr | - | |
ALKEM LABORATORIES Operating Profit
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 11.88 % |
| 5 Yr CAGR | 6.64 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,512 Cr | 11.88 | |
| Mar2025 | ₹2,245 Cr | 39.52 | |
| Mar2024 | ₹1,609 Cr | -21.60 | |
| Mar2023 | ₹2,053 Cr | 5.69 | |
| Mar2022 | ₹1,942 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 9.31 % |
| 5 Yr CAGR | -3.02 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 19.38% | 9.31 | |
| Mar2025 | 17.73% | 27.74 | |
| Mar2024 | 13.88% | -28.08 | |
| Mar2023 | 19.3% | -11.91 | |
| Mar2022 | 21.91% | - | |
ALKEM LABORATORIES Profit After Tax
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 20.59 % |
| 5 Yr CAGR | 8.11 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,165 Cr | 20.59 | |
| Mar2025 | ₹1,796 Cr | 82.47 | |
| Mar2024 | ₹984 Cr | -40.19 | |
| Mar2023 | ₹1,646 Cr | 3.82 | |
| Mar2022 | ₹1,585 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -9.15 % |
| 5 Yr CAGR | -1.32 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.43 % | -9.15 | |
| Mar2025 | 11.48 % | 22.78 | |
| Mar2024 | 9.35 % | 66.67 | |
| Mar2023 | 5.61 % | -49.00 | |
| Mar2022 | 11 % | - | |
ALKEM LABORATORIES Earnings Per Share (EPS)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 6.29 % |
| 5 Yr CAGR | 8.75 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹193 | 6.29 | |
| Mar2025 | ₹181 | 20.59 | |
| Mar2024 | ₹150 | 82.47 | |
| Mar2023 | ₹82 | -40.20 | |
| Mar2022 | ₹138 | - | |
ALKEM LABORATORIES Return on Capital Employed (ROCE)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | -1.30 % |
| 5 Yr CAGR | 3.30 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 21.28% | -1.30 | |
| Mar2025 | 21.56% | 10.45 | |
| Mar2024 | 19.52% | 49.12 | |
| Mar2023 | 13.09% | -29.96 | |
| Mar2022 | 18.69% | - | |
ALKEM LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹5,350.2 |
| Current MarketCap | : | ₹ 63,987.8 Cr |
| Updated EOD on | : | Aug 28,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | -0.1% |
-8% |
-2.1% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
ALKEM LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.1% | 1.6% | 15.3% |
| BSE 400 MIDSMALLCAP INDEX | 0.4% | 2.2% | 7.7% |
| BSE 150 MIDCAP INDEX | 0.3% | 1.9% | 8.4% |
| BSE 200 EQUAL WEIGHT | 0.1% | 0.7% | 7% |
| BSE 1000 | -0% | 1% | 2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 2.4% | 2.4% | 21.7% |
| NIFTY HEALTHCARE INDEX | 2.3% | 0.6% | 14.1% |
| NIFTY500 HEALTHCARE INDEX | 2% | 1.2% | 13.9% |
| NIFTY MIDSMALL HEALTHCARE | 1.8% | 1.1% | 17.5% |
| NIFTY500 SHARIAH | 0.8% | 0.8% | -0.7% |
You may also like the below Video Courses
FAQ about ALKEM LABORATORIES Financials
How the annual revenues of ALKEM LABORATORIES have changed ?
The Revenues of ALKEM LABORATORIES have increased by 2.34% YoY .
How the Earnings per Share (EPS) of ALKEM LABORATORIES have changed?
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 6.29 % YoY .
Check out Intrinsic Value of Peers of ALKEM LABORATORIES
Compare Stock Analytics of Peers of ALKEM LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
